|
| << previous | next >> |
Journal description
All volumes of the corresponding journal
All issues of the corresponding volume
All articles of the corresponding issues
Details for article 188 of 200 found articles
| Title: |
167TiP AdvanTIG-301: Anti-TIGIT monoclonal antibody (mAb) ociperlimab (OCI) + tislelizumab (TIS) + concurrent chemoradiotherapy (cCRT) followed by OCI + TIS or TIS + cCRT followed by TIS vs cCRT followed by durvalumab (DUR) in previously untreated, locally advanced, unresectable NSCLC |
| Author: |
Xing, L. Yu, J. Peters, S. Besse, B. Spira, A. Wang, J. Yang, Y. Wang, H. |
| Appeared in: |
Annals of oncology |
| Paging: | Volume 32 () nr. S7 pages S1455 |
| Year: |
2021 |
| Contents: | |
| Publisher: |
European Society for Medical Oncology |
| Source file: |
Elektronische Wetenschappelijke Tijdschriften |
Details for article 188 of 200 found articles
| << previous | next >> |